肝硬化与肝移植受者体重减轻的药物治疗:数据转化与未充分利用的潜力
综述探讨肝硬化患者和肝移植受者使用减肥药物及替代药物的数据;Liraglutide因药代动力学特性似乎总体安全,phentermine-topiramate减重潜力最高但需注意神经精神疾病、心血管合并症和药物相互作用;用药决策应基于肾肝功能、合并症和合并用药个体化。
要点
- 肝硬化患者约30%肥胖,移植后肥胖患病率增至>40%。
- Liraglutide基于药代动力学特性似乎总体安全。
- Phentermine-topiramate减重潜力最高但需考虑神经精神、心血管合并症及药物相互作用。
核心结论
- 减肥药物在肝硬化患者和肝移植受者中可行,但处方决策应基于肾和肝损伤程度、其他合并症及合并用药个体化。
研究设计与样本
- 综述,检索并分析肝硬化患者和肝移植受者中使用减肥药物(orlistat、phentermine-topiramate、naltrexone-bupropion、liraglutide)及替代药物的数据。
主要发现
- 肝硬化患者中约30%为肥胖,移植后肥胖患病率增至>40%。
- Liraglutide基于药代动力学特性似乎总体安全。
- Phentermine-topiramate似乎具有最高减重潜力,但需特别考虑神经精神疾病、心血管合并症和药物相互作用。
- 关于替代药物用于减重的数据正在涌现,但需要更多数据。
临床怎么用
- 作者认为减肥药物在该患者人群中可行,但选择药物应基于肾和肝损伤程度、其他合并症及合并用药个体化。
局限性
- 原文指出这些药物在肝硬化患者和肝移植受者中的数据匮乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Thirty percent of patients with cirrhosis are obese and the prevalence of obesity increases after transplant to >40% post-transplant. There are currently four weight loss medications approved by the FDA for treatment of obesity (orlistat, phentermine-topiramate, naltrexone-bupropion, and liraglutide). The aim of this review was to investigate the data on the use of these weight loss medications and alternative medicines in patients with cirrhosis and in liver transplant recipients (LTRs). APPROACH AND RESULTS: While there is paucity of data for these medications in patients with cirrhosis and LTRs, Liraglutide appears to be generally safe in view of its pharmacokinetic properties. Phentermine-topiramate seems to have the highest weight loss potential but special consideration should be given to neuropsychiatric disorders, cardiovascular comorbidities, and drug interactions. There are emerging data on use of alternative medicines for weight loss but more data are needed. CONCLUSIONS: The use of weight loss medications is feasible in this patient population but the decision of which medication to prescribe should be individualized based on the degree of renal and hepatic impairment, other co-morbidities, and concomitant medications.
引用
- Brown SA, Izzy M, Watt KD, et al. Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential. Hepatology. 2021. PMID: 33047343. doi:10.1002/hep.31595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。